Chong Kun Dang announces launching of Generic Evista tablets

Published: 2008-10-28 06:58:00

Updated: 2008-10-28 06:58:00

Chong Kun Dang Pharmaceutical Co. announced on October 23 that the company will market its generic version of Lilly's osteoporosis treatment (raloxifene hydrochloride) in the middle of next month.
“Our launching schedule was originally planned in July but delayed inevitably due to the import of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK